Overview of Adrafinil

Quick Facts

Property	Description
Active ingredient	Adrafinil (2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide)
Form	Tablets or Capsules
Pharmacological class	Eugeroic (Wakefulness-promoting agent)
General purpose	Promotes alertness and vigilance; counteracts excessive sleepiness
Origin	Synthetic compound

Adrafinil: A Eugeroic Wakefulness-Promoting Agent

Adrafinil is a synthetic compound that is classified as a eugeroic, placing it within the group of wakefulness-promoting agents. The compound, identified chemically as 2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide, functions as a single-ingredient product. This substance gained recognition in pharmacological studies for its ability to selectively influence pathways related to sustained wakefulness.

Its primary general purpose is to promote functional alertness and sustained vigilance, having been historically utilized to relieve excessive sleepiness in contexts requiring prolonged attention. This agent falls under a class of drugs that selectively enhance wakefulness, distinguishing it from traditional, generalized central nervous system stimulants.

Composition and Prodrug Relationship to Modafinil

Adrafinil is typically administered through the oral route, available in solid dosage forms such as tablets or capsules. The compound is notably classified as a prodrug. This means the substance itself is largely inactive until it undergoes mandatory hepatic metabolism (processing by the liver) to convert into its therapeutically active compound, Modafinil.

Clinical research confirms that Adrafinil’s ultimate pharmacological effect is mediated entirely by the subsequent presence of Modafinil in the systemic circulation. This necessity for liver conversion is the primary differentiating factor when comparing Adrafinil to its directly active analogue, Modafinil.

General Purpose: Supporting Vigilance and Alertness

The overall utility of the compound is rooted in the resultant eugeroic effect, which promotes consistent vigilance. This action enhances the ability to sustain attention and counter fatigue, supporting individuals in maintaining a functional level of wakefulness. The general purpose of the eugeroic class is focused on improving the overall quality of wakeful performance by selectively acting on pathways associated with alertness.

What side effects are possible with Adrafinil?

Adrafinil: Possible Side Effects and Safety Information

Adrafinil's safety profile is fundamentally shaped by its classification as a prodrug, which requires mandatory hepatic metabolism (processing by the liver) to convert into its active compound, Modafinil. This necessity establishes a primary regulatory constraint related to liver function and long-term exposure.

Officially Documented Adverse Reactions

Adverse reactions documented in official regulatory summaries are generally organized by the physiological systems affected, known as System-Organ Classes (SOCs):

System-Organ Class	Examples of Documented Effects
Hepatobiliary Disorders	Elevated liver enzymes (GGT, Alkaline Phosphatase)
Cardiac and Vascular Disorders	Potential for irregular heartbeat and increased blood pressure
Psychiatric Disorders	Potential for the exacerbation of psychosis symptoms
Gastrointestinal and Skin	Stomach pain, skin irritation, and anxiety
Nervous System Disorders	Reports of orofacial dyskinesia

Safety Constraints and Regulatory Status

Adrafinil is classified by the U.S. Food and Drug Administration (FDA) as an unapproved drug for therapeutic human use. Furthermore, its original market authorization in France was voluntarily discontinued following a regulatory assessment that determined an unfavorable risk-benefit ratio.

Population and Duration-Related Safety Notes

Regulatory safety constraints are specifically noted for several populations. These include older adults, who may have an increased potential for serious side effects, and individuals with pre-existing hepatic or heart conditions. Regarding duration, the elevation of liver enzymes is a safety concern documented as being associated with prolonged use.

Overdose and Emergency Response

Overdose and when to seek help for Adrafinil

Overdose information for Adrafinil is based on the established profile of its active metabolite, Modafinil, as documented in regulatory sources. Documented clinical manifestations of overdose primarily affect the Central Nervous System (CNS) and the Cardiovascular System.

CNS effects include agitation, excitation, insomnia, confusion, and tremor. Cardiovascular signs include palpitations, chest pain, and observed mild-to-moderate elevations of heart rate and blood pressure (tachycardia and hypertension).

Urgent Medical Action Required

Any suspected overdose necessitates seeking immediate medical attention and contacting emergency services. This urgent need is driven by the potential for severe adverse events, including tachyarrhythmias (rapid, irregular heart rhythms) and severe CNS effects, which may require hospitalization and continuous monitoring.

Management of an overdose is strictly symptomatic and supportive. Regulatory documents confirm that no specific antidote is known for this compound. Supportive procedural steps, such as gastric decontamination and the use of activated charcoal, may be considered, and continuous cardiovascular monitoring is required due to the specific documented effects on the heart.

Therapeutic Uses of Adrafinil

What Adrafinil Treats: Main Uses and Benefits

This eugeroic agent is commonly used to help with excessive daytime sleepiness (hypersomnia) and related decreased vigilance, providing supportive relief in situations where symptoms interfere with daily functioning. Its use is considered relevant in conditions involving episodic or fluctuating manifestations, like those related to excessive sleepiness and chronic vigilance disorders.

Adrafinil is applied across domains where additional symptomatic support is needed, typically to manage manifestations such as symptoms related to physical discomfort like excessive sleepiness, manifestations associated with age-related inattention and difficulties with focus, and symptoms of increased neurological or muscular activity such as psychomotor retardation. This supportive use may be part of symptomatic management for mild cognitive impairment and specific manifestations of mild depression where physical slowness is a key feature. It supports the patient during difficult episodes by easing distress and maintaining alertness.

“This agent is relevant in clinical settings marked by temporary physiological imbalance, where supportive relief is needed to maintain functional stability.”

Quick Fact: Management of Inadequate Vigilance
Symptom Category	Symptoms related to heightened physiological activity
Typical Context	Applied in scenarios where additional management of discomfort is required
Patient Benefit	Assists with maintaining functional stability and alertness

Eligibility and Restrictions for Use

Eligibility for Adrafinil: Official Regulatory Information

Adrafinil's eligibility profile is defined by restrictions related to its necessity for hepatic metabolism and the stimulant-like effects of its active metabolite. Use is strictly limited to certain populations as defined by regulatory guidance.

Eligibility Scope	Regulatory Wording
Allowed Population	Historically indicated for the elderly for disorders of vigilance and attention.
Contraindicated Groups	Patients with known hypersensitivity to Adrafinil or its metabolites. Individuals with uncontrolled hypertension or cardiac arrhythmias.

Condition-Specific Eligibility Rules

Use must be avoided in patients with pre-existing liver disease because the substance requires mandatory hepatic metabolism for conversion. Individuals with heart conditions, high blood pressure, or a mental disorder involving hallucinations and delusion (psychosis) should also avoid use due to the risk of exacerbation.

Age and Reproductive Restrictions

Adrafinil is not approved or not recommended for the pediatric population (under 18 years of age). Use must also be avoided during both pregnancy and breastfeeding, as the substance is officially categorized as possibly unsafe in these states.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Adrafinil is a prodrug that is rapidly converted in the body to modafinil, and its interaction profile is therefore determined by the properties of this active metabolite. The primary concern involves its ability to affect the metabolism of many other drugs through specific liver enzymes.

Key interaction domains are defined by the drug's effect on cytochrome P450 enzymes:

Steroidal Contraceptives: The drug is known to induce the CYP3A4/5 enzyme, which can significantly increase the metabolism of estrogen and progestin-containing birth control pills. This interaction results in the reduced effectiveness of oral contraceptives, requiring patients to use alternative or concomitant non-hormonal methods for the duration of treatment and for two months following discontinuation.
Anticoagulants (e.g., Warfarin): Due to potential inhibition of the CYP2C9 enzyme, the clearance of Warfarin may be slowed, potentially increasing its effects and the risk of bleeding. Regular monitoring of prothrombin time (INR) is required upon initiating therapy and following dose changes.
CYP2C19 Substrates: The drug inhibits CYP2C19, which can decrease the clearance and potentially increase the plasma concentrations of drugs metabolized by this pathway, such as certain antiepileptics (e.g., Phenytoin) and anti-ulcer medications (e.g., Omeprazole). Dose adjustment of the co-administered medication may be necessary.

Mechanism of Action

How Adrafinil Works: Mechanism of Action

Adrafinil's pharmacological activity is entirely dependent upon its initial conversion via hepatic metabolism into its active metabolite, Modafinil. This mandatory transformation results in a structurally-determined delayed onset of effect.

Atypical Modulation of Central Arousal Systems

The active metabolite primarily acts as a weak, atypical inhibitor of the Dopamine Transporter (DAT), slowing the reuptake of Dopamine and Norepinephrine into the presynaptic neuron. This increases the concentration of these monoamines in the synapse, enhancing signal transmission in circuits related to arousal and attention.

Crucially, the mechanism involves the targeted activation of the Orexin (Hypocretin) pathways in the hypothalamus, which are a primary physiological driver of the wake state, and indirectly promotes the release of Histamine. This effect shifts the Glutamate (excitatory) and GABA (inhibitory) balance toward greater neural excitability . This multi-system modulation results in selective activation of the arousal system (the eugeroic effect) through the suppression of inhibitory signals and the stabilization of wakefulness-promoting pathways, resulting in a wakefulness profile defined by selective activation rather than broad, generalized CNS excitation.

Dosage and Administration Information

Administration Guidelines (Eugeroic Class Principle)

Adrafinil is a prodrug that is converted by the liver into its active compound, Modafinil, which is the currently and widely regulated eugeroic agent. Due to the withdrawal of Adrafinil's marketing authorization, the instructions for its administration are governed by the established standards for this drug class.

Administration is strictly by the oral route, typically using tablets or capsules, which must be swallowed whole. Intake may occur with or without food; however, it is noted that food intake may delay the time required to reach maximum concentration in the blood by approximately one hour.

Dosing and Frequency

The recommended starting dose, based on the active metabolite equivalent, is 200 mg daily. This daily quantity is generally administered as a single dose in the morning to promote wakefulness during the daytime. An alternative is a divided dose, with one portion taken in the morning and the other at noon. Doses may be increased to a maximum of 400 mg per day in patients who do not show an adequate response to the starting regimen. For use related to shift work, the full dose is taken about one hour prior to the start of the work shift.

Specific Population Instructions

Labeling requires specific adjustments for certain patient groups:

Population Group	Administration Rule	Rationale
Severe Hepatic Impairment	The daily dose must be reduced by one-half.	The compound requires liver metabolism.
Geriatric Patients (over 65)	Start with a lower daily dose (e.g., 100 mg equivalent) and monitor closely.	Potential for reduced clearance.
Pediatric Patients (< 18)	Use is not recommended.	Safety and efficacy are not established.

For continuous administration, the use protocol mandates periodic re-evaluation of the need for ongoing treatment, especially for use extending beyond nine weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Research

Research has evaluated whether the compound stimulates specific receptors involved in modulating the body's sensory signals. Adrafinil is classified as a prodrug; it is metabolized in the liver to produce the active compound, modafinil. Early phase trials examined the clinical effects, focusing on absorption and tolerability in healthy volunteers.

Efficacy and Symptom Management

Pain Relief: Studies were conducted to see if the compound affected pain symptoms as measured by patient-reported scales over a 12-week period. Findings have been described as mixed across different patient populations studied.
Vigilance and Attention: Historically, research investigated the compound's use in relation to deficits in vigilance, attention, memory, and fatigue, particularly in older adult populations. A French marketing authorization committee reviewed these studies and, in 2011, was unable to conclude that Adrafinil provided benefit.

Tolerability and Safety Profile

Observed Side Effects: Common observations in clinical studies included mild gastrointestinal distress and transient fatigue. These effects were generally reported as mild, and participant withdrawal due to observed effects remained low in the studies.
Safety Concerns: Because the compound is metabolized by the liver, prolonged use has been associated with the potential for elevated liver enzymes and hepatotoxicity (liver damage). Post-marketing case reports have also described the occurrence of orofacial dyskinesia (involuntary facial movements) in one patient following long-term administration. The compound has been removed from the market in France.

Regulatory Status and Next Steps

The compound is one compound that has been researched in the domain of chronic physical symptoms. Ongoing research is currently exploring its use in relation to other conditions involving chronic systemic issues. Adrafinil is an unapproved drug in jurisdictions like the United States and is not regulated by agencies such as the FDA.

Key Studies & References

Modafinil - LiverTox - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Adrafinil (FAQ)

Q: How long does it typically take for Adrafinil's effects to begin?

Adrafinil is classified as a prodrug, meaning it must first be metabolized by the liver into its active compound, Modafinil. Due to this necessary conversion process, the effects of Adrafinil have a delayed onset compared to its active form. Official pharmacological information indicates the active compound typically reaches its highest concentration in the blood between one and four hours after oral intake.

Q: What are the signs of a potential severe or adverse reaction to Adrafinil?

Official drug information for the drug class describes potential severe reactions that have been described in official documents as serious. Documented effects include signs of an allergic reaction, such as swelling of the face, eyes, lips, or tongue, and difficulty breathing. Serious changes in mood or behavior, such as confusion, hallucinations, or new psychiatric symptoms, are also documented possibilities.

Q: What countries still authorize or list Adrafinil for medical use?

The regulatory status of Adrafinil is limited in major markets. Its original marketing authorization in France was voluntarily discontinued, and it is classified as an unapproved drug for therapeutic human use in the United States. This means it is not approved for prescription use by key regulatory bodies like the FDA or EMA.

Q: Is Adrafinil a controlled substance in the US?

Adrafinil itself is generally not listed as a controlled substance in the United States. However, its active metabolite, Modafinil, is classified by the US Drug Enforcement Administration (DEA) as a Schedule IV controlled substance. This scheduling is based on the compound's potential for abuse.

Q: What is the history of Adrafinil's development?

Adrafinil was originally discovered by Lafon Laboratories in the late 1970s. It was historically marketed in France under the trade name Olmifon. This information provides context on the drug's origin prior to its withdrawal from major pharmaceutical markets.

Q: Can Adrafinil be bought legally without a prescription in some regions?

As an unapproved drug for therapeutic human use in major jurisdictions, Adrafinil is not subject to formal prescription controls. Because it lacks regulatory approval, its sale and distribution are often subject to regulatory action regarding it being sold as an unapproved and misbranded product.

Q: Is Adrafinil considered a nootropic according to scientific definitions?

Official regulatory documents do not use or define the term 'nootropic' for this compound. However, the World Anti-Doping Agency (WADA) banned Adrafinil and its active metabolite in 2004, classifying them as non-specified stimulants. Furthermore, the US FDA has issued warnings regarding unapproved substances marketed as 'nootropics.'

Q: How long do the effects of Adrafinil usually last after use?

The duration of the compound's effect is determined by its active form, Modafinil. The official pharmacological profile for Modafinil indicates an elimination half-life that typically ranges from 10 to 17 hours after a single dose.

Q: Are headaches a frequent side effect mentioned in general user experiences?

Clinical studies involving the active compound, Modafinil, indicate that headache is listed as one of the most commonly reported side effects observed during trials. Other common adverse reactions include gastrointestinal distress and anxiety.

Q: Are there known interactions between Adrafinil and common stimulants like caffeine?

Adrafinil's active compound is classified as a central nervous system (CNS) stimulant. Official drug information describes potential concerns regarding combining it with other stimulants like caffeine. This is due to the potential for additive effects on heart rate and blood pressure.

Q: What information is available regarding combining Adrafinil with alcohol?

Based on official regulatory information for related active compounds, the consumption of alcohol should be avoided while using the substance. This cautionary statement is due to the potential for altered effects and serious adverse events.

Q: Can people who drive or operate machinery use Adrafinil?

Official warnings for the drug class state that the substance can affect judgment, coordination, and reaction time. Patients are cautioned against driving or operating complex machinery until they know how the substance affects them personally.

Q: Does Adrafinil typically cause a false positive on a standard workplace drug screening test?

The World Anti-Doping Agency (WADA) has banned Adrafinil and its active metabolite. While it is detectable, analytical studies show that some common drug screening tests may detect the compound or its metabolites, although the results are distinct from standard illicit drugs.

Q: Is Adrafinil structurally similar to or related to amphetamines?

Regulatory texts state that the active metabolite, Modafinil, has wake-promoting actions that are similar to those of sympathomimetic agents such as amphetamine. However, official information clarifies that its pharmacological profile and chemical structure are not identical to traditional amphetamines.

Q: Is Adrafinil known to affect or alter a person's appetite?

Clinical information for the active compound, Modafinil, lists a change in appetite as one of the possible adverse reactions. Specifically, loss of appetite is cited in official reports.

Q: What does the evidence say about Adrafinil and the potential for dependence or withdrawal symptoms?

The active compound, Modafinil, is classified by the US DEA as a Schedule IV controlled substance, which indicates a low potential for abuse. Clinical experience described in official documents suggests that dependence and withdrawal symptoms, if they occur, are generally mild.

Q: How is Adrafinil categorized in terms of its abuse potential by international drug agencies?

Adrafinil's abuse potential is primarily assessed through its active metabolite, Modafinil. The US Drug Enforcement Administration (DEA) classifies Modafinil as a Schedule IV controlled substance, which means it has a low potential for abuse relative to drugs in Schedule III.

How should Adrafinil be stored and disposed of?

Storage and Disposal of Adrafinil

Adrafinil is an unapproved drug in the United States, and its marketing authorization in Europe has been withdrawn. Consequently, no active governmental labeling exists to define product-specific storage temperature, light protection, or container requirements.

Storage and Handling

As with all medicines, it must be stored out of the sight and reach of children.

Storage Requirement	Status
Temperature/Light Protection	Undefined by active official labeling
Child Safety	Store out of sight and reach of children

Official Disposal Instructions

When disposing of unused or expired medicine for which no specific instructions are provided on the label, two main procedures are advised by health authorities:

Drug Take-Back Programs are the preferred method for returning unused product.
If a take-back program is unavailable, the drug must be removed from its container, mixed with an undesirable substance (e.g., dirt or coffee grounds), and sealed in a bag or container before being placed in household trash. All identifying information must be removed from the original packaging.

Adrafinil